 | | Vol. 8.25 – 15 July, 2022 |
| |
|
|
| Researchers showed using intravital microscopy that, despite similarities in the number and distribution of proliferative cells with an Lgr5 signature in mice, small intestinal crypts contained twice as many effective stem cells as large intestinal crypts.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists derived and applied a consensus mesenchymal-subtype gastric cancer (Mes-GC) classifier to define the Mes-GC enhancer landscape, revealing disease vulnerabilities.
[Gut] |
|
|
|
| The authors reported that interfering with de novo fatty acid synthesis by deletion of the enzyme Acetyl-CoA-Carboxylase 1 in intestinal epithelial cells resulted in the loss of epithelial crypt structures and a specific decline in Lgr5+ intestinal epithelial stem cells.
[Nature Communications] |
|
|
|
| Investigators showed that tumor cell-derived angiopoietin-like protein 2 (ANGPTL2) promoted β-catenin-driven intestinal tumorigenesis.
[Oncogene] |
|
|
|
| Researchers reported that low activating transcription factor 2 (ATF2) levels correlated with worse prognosis and tumor aggressiveness in colorectal cancer patients.
[Cellular and Molecular Life Sciences] |
|
|
|
| Scientists investigated the anti-proliferative effect of some Indian honeys and analyzed their mechanism of action in colon cancer.
[Food & Function] |
|
|
|
| High expression of circular low-density lipoprotein receptor (circLDLR) was found in colorectal cancer (CRC) tissues and cells and was closely associated with the malignant progression and poor prognosis of CRC patients.
[Cell Death Discovery] |
|
|
|
| Researchers analyzed the effect of latent membrane protein 2A (LMP2A) on the gene expression of gastric cancer cells by transcriptome sequencing on the gastric cancer cell line SGC7901 that expressed LMP2A.
[Virus Genes] |
|
|
|
|
| Investigators analyze the relevant targets when drugs or inhibitors act on the Wnt pathway, to clarify the medication ideas of drugs or inhibitors for the treatment of diseases, especially colorectal cancer.
[Molecular Cancer] |
|
|
|
|
| Leap Therapeutics, Inc. announced the initiation of Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap’s DKK1 antibody, with tislelizumab, BeiGene’s anti-PD-1 antibody, and chemotherapy compared to a tislelizumab and chemotherapy control arm.
[Leap Therapeutics, Inc.] |
|
|
|
|
| December 3 – 7, 2022
Washington, DC, United States |
|
|
|
|
|
| | University Hospital Aachen – Aachen, Germany |
|
|
|
| | University of Twente – Enschede, Netherlands |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | The Chinese University of Hong Kong – Hong Kong, China |
|
|
|
| | Tampere University – Tampere, Finland |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
